Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00965276 · ClinicalTrials.gov registry record
Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 2,500
- Enrollment target
NCT00965276: Completed study, sponsored by National Cancer Institute (NCI).
NCT00965276 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00965276 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 2,500 participants
- Enrollment target
Study Summary
This study will examine the relationship of a protein called pAKT to survival of breast cancer patients with one or more positive axillary lymph nodes. Akt plays a role in cell survival, tumor formation, and the development of drug resistance. The study will use tumor tissue obtained from 2,000 patients enrolled in a National Surgical Adjuvant Breast and Bowel Project study that is evaluating whether adding the drug paclitaxel (Taxol (Registered Trademark)) to a treatment regimen of doxorubicin (Adriamycin (Registered Trademark)) and cyclophosphamide (Cytoxan (Registered Trademark)) improves disease-free survival and overall survival in patients with node-positive breast cancer. The current study will measure levels of pAkt in the tissues and correlate the results with clinical outcome to see if pAkt levels are associated with improved patient survival. ...
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2004-01-13 |
| Est. Completion | 2010-12-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00965276
The ClinicalTrials.gov registry entry for NCT00965276 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00965276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00965276 about?
NCT00965276 is a clinical study titled "Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer". This study will examine the relationship of a protein called pAKT to survival of breast cancer patients with one or more positive axillary lymph nodes. Akt plays a role in cell survival, tumor formation, and the development of drug resistance. The study will use tumor tissue obtained from 2,000 pat...
What is the current status of trial NCT00965276?
This trial is currently completed. The enrollment target is 2,500 participants. The study started on 2004-01-13. Estimated completion is 2010-12-14.
Who is sponsoring clinical trial NCT00965276?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.